Status:
ACTIVE_NOT_RECRUITING
Efficacy of Topical Cannabidiol for Eczema
Lead Sponsor:
Khon Kaen University
Conditions:
Chronic Pruritus
Eczema
Eligibility:
All Genders
25+ years
Phase:
PHASE2
Brief Summary
Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life. Chronic pruritic skin conditions such as ...
Eligibility Criteria
Inclusion
- All participants must be aged 25 years or older.
- Patients must be diagnosed with eczema, including atopic dermatitis, nummular eczema, lichen simplex chronicus, or prurigo nodularis, with pruritus persisting for more than 6 weeks.
- Patients must be willing to refrain from using other topical products throughout the 4-week study period.
- Patients must provide written informed consent to participate in the study.
Exclusion
- Patients who have taken oral steroids, immunosuppressive drugs, or received phototherapy within the past 3 months.
- Patients with chronic kidney disease, liver cirrhosis, cancer, or thyroid disease.
- Pregnant or breastfeeding women, or women planning to become pregnant.
- Patients who develop erythematous itchy rash in response to an open patch test using cannabis extract products.
- Patients with a known allergy to cannabis-derived products, which may result from other ingredients and/or solvents used in the extraction process.
- Patients with severe or unstable cardio-pulmonary diseases (e.g., angina, peripheral vascular disease, cerebrovascular disease, or arrhythmia), or those at risk of cardiovascular disease.
- Patients with a history of psychosis, current active mood disorder, or anxiety disorder.
- Patients who are addicted to substances, including nicotine, or are heavy alcohol users.
- Patients using other medications, particularly opioids or sedatives such as benzodiazepines.
- Patients taking medications known to potentially interact with cannabis extracts, such as warfarin, fluoroquinolones, or dihydropyridine calcium channel blockers.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06994520
Start Date
May 1 2025
End Date
December 31 2026
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Khon Kaen University
Khon Kaen, Changwat Khon Kaen, Thailand, 40002